With MET amplification serving as a general resistance mechanism to targeted therapies in lung cancer, it is crucial to be able to detect MET amplification in a reliable manner, in order to identify the appropriate patients who can benefit from MET-targeting therapy. The gene discussed is MET; the disease is lung cancer.